SensoDetect has signed a LOI (letter Of Intent) with a South Korean distributor. The parties met for the first time this summer in connection with a major conference in the Copenhagen area and now, after a second meeting, the parties agreed on the bases for further cooperation as clarified in the LOI. The aim is to soon take the next step towards a distribution agreement primarily for the South Korean market. The timetable for cooperation is in line with the plan SensoDetect set up for the launch of the new BERA 3.0. The aim is therefore to set the foundations of the cooperation agreement as soon as possible, beginning at 2018. This agreement is divided into a few steps to ensure a positive development in a large and interesting market. Initially, SensoDetect, together with the distributor's healthcare partners in South Korea, make a smaller study to ensure that the tests provide the same response for this population. At the same time, additional opportunities for refinement and development of specific markers for a new population are created. The focus will be on ADHD in the first step. After the BERA technology has been verified on the local market, the intention is that the distributor should aim to bring the technology as a standard for the diagnosis support of ADHD in South Korea. The first step in the launch is to clinicians with larger volumes and it is expected that current clinics will do at least 600 measurements per year and machine. BERA has a capacity of considerably higher volumes, but SensoDetects strategy is to charge per test, so it requires primarily only a minimum number to sign contracts. ROI (Return On Investment) for BERA is estimated at about 3-6 Months.